SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH M impact

Johnson & Johnson to Acquire Ollin Biosciences

Johnson & Johnson will acquire Ollin Biosciences and its late-stage bispecific antibody for ophthalmology.

JNJ

Story updates

01:00:59 PM UTC
SquawkNews
Johnson & Johnson (NYSE:JNJ) today announced it has entered into a definitive agreement to acquire Ollin Biosciences, Inc., (“Ollin”) a clinical-stage biopharmaceutical company developing therapies for serious eye diseases, for $2.2 billion upfront, with the potential for additional regulatory and…
01:01:12 PM UTC
SquawkNews
Johnson & Johnson agreed to acquire Ollin Biosciences for $2.2B upfront, plus potential regulatory and commercial milestone payments. A separate development funding agreement would support OLN324’s Phase 3 advancement, contingent on acquisition close.Material DetailsContext by AI AnalystThis is a p…
01:01:31 PM UTC
SquawkNews
Johnson & Johnson To Acquire Ollin Biosciences for Initial $2.2 Billion >JNJ
01:07:45 PM UTC
SquawkNews
J&J strikes $2.2 billion buyout deal for eye disease biotech Ollin Biosciences

Related stories